

Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

LI-COR: ODYSSEY M Imaging System

RRID:SCR_025709

Type: Tool

Proper Citation

LI-COR: ODYSSEY M Imaging System (RRID:SCR_025709)

Resource Information

URL: <https://www.licor.com/bio/odyssey-m/>

Proper Citation: LI-COR: ODYSSEY M Imaging System (RRID:SCR_025709)

Description: Imager has multiple detection modes with up to 19 fluorescent and luminescent channel combinations to power wide range of assays including 3-Color Quantitative Western Blots, 3-Color In-Cell Western Assays, Cell Analysis Studies, ELISA, Tissue Section Imaging, Viral Titration Assays. Imager includes sCMOS image sensor and 5-micron resolution.

Synonyms: ODYSSEY M, LI-COR ODYSSEY M

Resource Type: instrument resource

Keywords: Imager, fluorescent channels, luminescent channels, sCMOS image sensor, 5-micron resolution,

Specification URL:

<https://licor.app.boxenterprise.net/s/uefo3m8svkjfxnthwo0hf1de944tpvft>

Resource Name: LI-COR: ODYSSEY M Imaging System

Resource ID: SCR_025709

Alternate IDs: SCR_025680

Record Creation Time: 20240911T053249+0000

Record Last Update: 20260808T190729+0000

Ratings and Alerts

No rating or validation information has been found for LI-COR: ODYSSEY M Imaging System.

No alerts have been found for LI-COR: ODYSSEY M Imaging System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

L??pez-Fuentes E, et al. (2026) Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities. *Cancer discovery*, 16(2), 296.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(8), 2042.

Bilusic M, et al. (2026) The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients. *EMBO molecular medicine*, 18(5), 1551.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. *Cancer research*, 86(11), 2688.

Laarne M, et al. (2025) Characterization of novel CASQ1 variants in two families with unusual phenotypic features. *Journal of neurology*, 272(12), 789.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. *Cancer research*, 85(22), 4380.

Minten EV, et al. (2022) Protocol for in vitro lysine deacetylation to test putative substrates of class III deacetylases. *STAR protocols*, 3(2), 101313.

Counihan NA, et al. (2017) Plasmodium falciparum parasites deploy RhopH2 into the host erythrocyte to obtain nutrients, grow and replicate. *eLife*, 6.